A controlled, double-blind study of dl-alpha-tocopheryl nicotinate (Juvela-Nicotinate) for treatment of symptoms in hypertension and cerebral arteriosclerosis.
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005121:Extremities; D005260:Female; D006257:Head; D006801:Humans; D006973:Hypertension / Q000150:complications*; D002537:Intracranial Arteriosclerosis / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009333:Neck; D009461:Neurologic Manifestations; D009539:Nicotinic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D007319:Sleep Initiation and Maintenance Disorders / Q000209:etiology; D013997:Time Factors; D014717:Vertigo / Q000209:etiology; D014810:Vitamin E / Q000009:adverse effects / Q000627:therapeutic use*
D009539:Nicotinic Acids; D010919:Placebos; D014810:Vitamin E